Skip to main content

Table 2 Comparison between tocilizumab and abatacept initiators in terms of mean change in CDAI, mean change in mHAQ, and achievement of low disease activity from baseline to 6 months

From: Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

Outcome Tocilizumab initiators (n = 264) Abatacept initiators (n = 264) Unadjusted differencea abatacept vs tocilizumab
Continuous Mean ± SD Mean ± SD β (95% CI) p value
 Change in CDAI n = 259, –9.9 ± 14.1 n = 257, –11.3 ± 14.7 –1.27 (–3.65, 1.11) 0.30
 Change in mHAQ n = 263, –0.11 ± 0.49 n = 264, –0.12 ± 0.42 –0.01 (–0.09, 0.06) 0.83
Binary Response rate Response rate OR (95% CI) p value
 Achievement of LDA n = 259 n = 257   
(CDAI at time of switch was imputed for switchers) 86 (33.2%) 85 (33.1%) 0.99 (0.69, 1.43) 0.97
  1. aMatched pair as the random effect
  2. CDAI Clinical Disease Activity Index, CI confidence interval, LDA low disease activity, mHAQ modified Health Assessment Questionnaire, OR odds ratio